



ResApp strengthens patent position in Europe

Brisbane, Australia, 2 February 2021 – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that the European Patent Office has issued a Notice of Allowance for the company's patent titled, "Methods and apparatus for cough detection in background noise environments."

The patent covers the use of machine learning audio processing techniques for identifying cough sounds in environments with significant background noise. The technology covered in the patent is used in ResApp's smartphone-based respiratory diagnostic test ResAppDx.

The patent is owned by ResApp Health. ResApp has additional patent applications covering similar subject matter pending in Australia, Japan, China, India and the United States.

CEO and Managing Director Dr Tony Keating said: *"We have a number of near-term growth initiatives planned for the European market and this patent grant is an important milestone in building a comprehensive patent portfolio in Europe."*

"This particular innovation was developed internally by our team to overcome the challenges of using sound-based algorithms in the real-world, where there is little control around background noise. This innovation allows us to deploy our cough-based technology into multiple settings, from clinical use cases in busy emergency departments to telehealth use and health monitoring in the home."

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.



Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.